Evidence map›Paper›PMID 28185712›Full record

ReviewJournal of diabetes and its complications2017

The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.

Beibei Xu, Dragana Lovre, Franck Mauvais-Jarvis

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and its complications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. An update on selective estrogen receptor modulator: repurposing and formulations.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Beibei XuDepartment of Medicine, Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA, USA.
Dragana LovreDepartment of Medicine, Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA, USA.
Franck Mauvais-JarvisDepartment of Medicine, Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA, USA. Electronic address: fmauvais@tulane.edu.
Tulane University · US

Funding

Targeting the estrogen receptor-α to protect functional β-cell mass in womenR01DK074970 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Franck Mauvais-Jarvis · 2007 to 2026
$6.0M
Repurposing estrogens to improve pancreatic islet transplantationR01DK107444 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI MAUVAIS-JARVIS, FRANCK · 2016 to 2019
$1.5M
NIDDK NIH HHS R01 DK074970NIDDK NIH HHS R01 DK107444
6 · The paper itself

Abstract

Selective estrogen receptor modulators (SERMs) are a class of compounds that interact with estrogen receptors (ERs) and exert agonist or antagonist effects on ERs in a tissue-specific manner. Tamoxifen, a first generation SERM, is used for treatment of ER positive breast cancer. Raloxifene, a second generation SERM, was used to prevent postmenopausal osteoporosis. The third-generation SERM bazedoxifene (BZA) effectively prevents osteoporosis while preventing estrogenic stimulation of breast and uterus. Notably, BZA combined with conjugated estrogens (CE) is a new menopausal treatment. The menopausal state predisposes to metabolic syndrome and type 2 diabetes, and therefore the effects of SERMs on metabolic homeostasis are gaining attention. Here, we summarize knowledge of SERMs' impacts on metabolic, homeostasis, obesity and diabetes in rodent models and postmenopausal women.

Indexed as

AgingInsulin ResistanceModels, BiologicalAnimalsAntineoplastic Agents, HormonalBone Density Conservation AgentsDiabetes Mellitus, Type 2Energy MetabolismFemaleHumansIndolesObesityRaloxifene HydrochlorideSelective Estrogen Receptor ModulatorsTamoxifenAntineoplastic Agents, HormonalbazedoxifeneBone Density Conservation AgentsIndolesRaloxifene HydrochlorideSelective Estrogen Receptor ModulatorsTamoxifenBazedoxifeneDiabetesEnergy metabolismMetabolic syndromeSelective estrogen receptor modulatorsSteatosis

Identifiers

PMID28185712
PMCPMC5350049
OpenAlexW2578294307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.